REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
7

Finishing Thymosin Alpha-1 — Final Progress Report

Gray Fox·about 1 month ago
Final progress report on Thymosin Alpha-1 after completing my full planned protocol. This was my first experience with this peptide and I approached it as a systematic experiment. Setup: I established a 2-week baseline period before starting, tracking all the same metrics I would track during the protocol. This gave me a solid comparison point. Results summary: net positive across recovery, sleep, and joint health metrics. The improvements were moderate rather than dramatic, which is exactly what I expected based on the published literature and realistic user reports. Best result: recovery between training sessions. I was consistently able to train at higher frequencies without accumulated fatigue. Over 12 weeks this added up to significantly more productive training volume. Most disappointing: I expected more impact on body composition based on some reports I had read. The effect was minimal for me, though I acknowledge my diet was only loosely controlled. Would I recommend Thymosin Alpha-1? Yes, with caveats. Set realistic expectations, commit to at least 8 weeks, track your metrics, and get bloodwork. The people who are disappointed are usually the ones who expected too much too fast.

Comments (5)

Avery HortonDEMO·about 1 month ago

Appreciate the honest assessment. Too many Thymosin Alpha-1 reviews read like advertisements. The moderate but meaningful improvement you describe is exactly what I experienced as well. I think the community benefits more from realistic reports like this than from overhyped claims.

4
Nico GrantDEMO·about 1 month ago

Question for you: did you get bloodwork done before and during your Thymosin Alpha-1 protocol? I am about to start and trying to decide which panels to run. Obviously the basics but curious if there are any specific markers that are particularly informative for tracking Thymosin Alpha-1 response.

5
Sage CrawfordDEMO·about 1 month ago

I ran Thymosin Alpha-1 at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

2
Jude BridgesDEMO·about 1 month ago

The sleep improvement you mention with Thymosin Alpha-1 has been the most universally reported benefit I see across different users. It seems like regardless of primary goals, almost everyone reports better sleep quality. I wonder if this is a direct effect or downstream from other physiological changes.

3
Chris BarkerDEMO·about 1 month ago

Thanks for the detailed protocol breakdown. I am starting Thymosin Alpha-1 next week and this is exactly the kind of practical information I was looking for. The reconstitution tips especially — I have seen conflicting advice elsewhere about water temperature and injection speed. Your approach sounds well-reasoned.

4

Sign in to comment.